Compound Guide• 9 min read
BPC-157 Explained: How It Works, Research Uses & Safety
BPC-157 (Body Protection Compound) is a stable 15-amino-acid pentadecapeptide derived from a protective sequence in human gastric juice. It has been studied for almost three decades for its effects on tissue repair, angiogenesis, gastrointestinal protection, and tendon/ligament healing in animal models.
What BPC-157 is
BPC-157 is a synthetic 15-amino-acid sequence (Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val) corresponding to a fragment of a larger 'body protection compound' identified in gastric juice. Unlike most peptides it is stable in stomach acid, which is why oral, intraperitoneal, and subcutaneous research administrations have all been studied.
Mechanism of action
BPC-157 does not bind a single named receptor. Current literature attributes its effects to multiple pathways: upregulation of vascular endothelial growth factor receptor 2 (VEGFR2), nitric-oxide system modulation, dopaminergic and serotonergic system effects, and stabilization of the transcription factor BACH1 via FBXO22, which drives angiogenesis (Cell Communication and Signaling, 2026).
The net observable effect across preclinical models is accelerated formation of new capillaries at injury sites and accelerated migration of fibroblasts and tenocytes.
Research areas with the most data
- Tendon and ligament healing in rat Achilles transection models
- Gastrointestinal ulcer protection across NSAID, alcohol, and stress models
- Inflammatory bowel disease models — reduced colitis severity
- Muscle crush injury and post-injury function recovery
- Vascular occlusion and ischemia/reperfusion injury
Dosing in published research
Rodent studies most commonly use 10 µg/kg or 10 ng/kg administered subcutaneously, intraperitoneally, or in drinking water. Both doses produce comparable healing effects in many models, suggesting the response curve is non-linear.
Most research-grade vials are 5 mg or 10 mg lyophilized, reconstituted in bacteriostatic water at 1 mg/mL. This is suitable for multi-week study designs across multiple subjects.
Safety findings in the literature
A 2025 scoping review in Current Reviews in Musculoskeletal Medicine concluded BPC-157 has a broadly favorable preclinical safety profile, with no reported organ toxicity at standard research doses. The same review emphasized that controlled human trials are still lacking and that any extrapolation beyond laboratory contexts is unsupported.
BPC-157 is on WADA's prohibited list (S0 — non-approved substances) for in-competition sport. It is not approved by the FDA for human therapeutic use.
FAQ
Is BPC-157 FDA approved?
No. BPC-157 is not approved by the FDA for any human therapeutic indication. It is sold strictly as a research reagent.
Is BPC-157 legal to buy in the US?
Yes, for laboratory research use. It is not legal to market or sell BPC-157 as a dietary supplement or drug.
What's the difference between oral and injectable BPC-157?
BPC-157 is acid-stable, so both routes appear in the literature. Subcutaneous administration is most common in injury-model research; oral dosing is more common in GI-protection studies.